Provider review, September 2026
Biopreventative carries a September 2025 federal warning letter whose opening line names its own website. It also publishes three incompatible answers to the question of which states it serves, one of which lists Alaska on a page where its own product pages exclude it.
Biopreventative is not a paid partner; this link may earn a commission if that changes. Full disclosure.
A warning letter issued in September 2025 is attached here on the entity rather than on a coincidence of names.
Its opening cites biopreventative.com as the content the agency reviewed, and its recipient block reads Biopreventative Company LLC dba Biopreventative at a Miami address, with a support address at the same domain.
The seller's own paperwork is less settled than the letter is: its terms name a limited liability company and its footer names an incorporated one.
Its home page says its physicians are licensed in all fifty states. Its weight-loss pages say it serves customers in all states except Alaska and Mississippi.
Its states-we-service page then lists Alaska for both drugs, omits Louisiana entirely without ever naming it as excluded, omits Alabama for semaglutide and omits California for tirzepatide.
No two of those three agree, so no state list is recorded here at all. A buyer in any of the disputed states has to confirm by telephone before paying.
The site says plainly that a reader's price holds only while their dose stays under a stated ceiling — one level for semaglutide, a higher one for tirzepatide — and names the monthly increase above it.
Every package price is restated as a daily and a monthly figure, and each of those restatements divides out correctly against the total printed beside it.
Its sermorelin page is the exception to that tidiness: the same figure appears as a discounted first month, struck through from a higher anchor, and as the standing rate for every month after.
In its own words, "a provider may prescribe a compounded drug, which is prepared by a state-licensed sterile compounding pharmacy partner. Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved."
It adds that the agency "does not evaluate compounded products for safety, effectiveness, or quality", which is the correct statement of the position.
That partner pharmacy is described but never named, no laboratory work is included in the fee, and its terms of service were last revised in 2022.
Biopreventative received an FDA warning letter issued September 2025. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Auren Rx names both its prescribing group, Wasef Health, and its dispensing pharmacy, VialsRX in Houston, with street addresses and phone numbers, and lets a subscriber pause an auto-refill plan on NAD+, sermorelin, glutathione or GHK-Cu instead of forcing a full cancellation.
Auren Rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Auren RxYes, one issued in September 2025. Its opening line names biopreventative.com and its recipient block names Biopreventative Company LLC at its Miami address.
Its weight-loss pages say Alaska is excluded and its states-we-service page lists Alaska for both drugs. The site contradicts itself, so confirm directly before ordering.
Only up to a stated ceiling. Above that, the seller says the monthly price rises by a fixed amount, and it names a different increase for each of the two molecules.
It says a state-licensed sterile compounding pharmacy partner does, but it never names the company.
Biopreventative is not a paid partner; this link may earn a commission if that changes. Full disclosure.